News
DCOY
5.15
-5.33%
-0.29
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at DCOY last week (0504-0508)?
Weekly Report · 1d ago
Decoy Therapeutics Q1 EPS $(4.18) Misses $(4.08) Estimate
Benzinga · 3d ago
Decoy Therapeutics Q1 net loss widens to $2.22 million
PUBT · 4d ago
Decoy Therapeutics: Q1 Earnings Snapshot
Barchart · 4d ago
Weekly Report: what happened at DCOY last week (0427-0501)?
Weekly Report · 05/04 09:33
Decoy Therapeutics executives present at peptide therapeutics conferences in Boston
PUBT · 04/27 12:45
Weekly Report: what happened at DCOY last week (0420-0424)?
Weekly Report · 04/27 09:34
Weekly Report: what happened at DCOY last week (0413-0417)?
Weekly Report · 04/20 09:32
Weekly Report: what happened at DCOY last week (0406-0410)?
Weekly Report · 04/13 09:34
Decoy Therapeutics to present at virtual investor Closing Bell event
Reuters · 04/09 12:36
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
PR Newswire · 04/09 12:36
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/07 21:05
Decoy Therapeutics CEO to join Virtual Investor Closing Bell webcast on business outlook
Reuters · 04/06 13:15
DECOY THERAPEUTICS TO PARTICIPATE IN VIRTUAL INVESTOR CLOSING BELL EVENT HIGHLIGHTING BUSINESS OUTLOOK FOR 2026
Reuters · 04/06 13:15
Weekly Report: what happened at DCOY last week (0330-0403)?
Weekly Report · 04/06 09:34
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split
TipRanks · 04/02 13:48
Decoy Therapeutics Regains Nasdaq Compliance
Benzinga · 04/02 13:05
DECOY THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 04/02 13:00
Decoy Therapeutics FY25 net loss widens to $12.5 million; R&D expenses climb to $8.9 million
Reuters · 03/31 21:06
More
Webull provides a variety of real-time DCOY stock news. You can receive the latest news about DECOY THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About DCOY
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.